Shares of Novo Nordisk fell sharply after the company once again lowered its annual forecast, citing ongoing supply challenges for its blockbuster obesity drug Wegovy. Despite a 25% jump in second-quarter sales and a 28% rise in net profit, the Danish drugmaker scaled back expectations for full-year operating profit and sales growth.

The company now anticipates operating profit to increase by 31–37%, down from its earlier guidance of 36–44%. Similarly, it expects sales growth of 24–30%, compared to the prior 27–33% estimate. The revisions come as Novo Nordisk struggles to keep up with the surging global demand for Wegovy, which has quickly become a market leader in the obesity drug segment.

The company remains committed to ramping up production but acknowledged that capacity limitations will persist in the short term. Analysts say the supply bottlenecks could hinder Novo’s ability to fully capitalise on the booming obesity treatment market.